Biogen Idec Expands its Portfolio with ALS Drug Candidate

By Heather Cartwright

Pharma Deals Review: Vol 2010 Issue 7 (Table of Contents)

Published: 28 Sep-2010

DOI: 10.3833/pdr.v2010.i7.1379     ISSN: 1756-7874

Section: Licensing



Biogen Idec has signed an exclusive licensing deal with Knopp Neurosciences, potentially worth US$345 M, for a Phase II drug candidate for the treatment of amyotrophic lateral sclerosis...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details